X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, NRx will focus on the NRX-100 (ketamine HCl), NMDA 3A inhibitor. It is being evaluated in Phase III clinical trial studies with patients for the treatment of Bipolar Depression and related to Suicidal Ideation.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: NRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2023
Details:
The agreement aims to develop a drug discovery platform that targets Tumor Macrophage Hybrid (TMH) cells to eliminate the most resilient cancers and stop disease recurrence.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: TFC Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 17, 2023
Details:
Under the licensing agreement, Tonix will develop a portfolio of fully human (TNX-3600) and murine (TNX-4100) mAbs for the treatment or prophylaxis of SARS-CoV-2 infection. TNX-3600 are generated from SARS-CoV-2+ asymptomatic individuals or COVID-19 convalescent patients.
Lead Product(s): TNX-3600
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-3600
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 13, 2023
Details:
Actimab-A (lintuzumab-Ac-225) is an Actinium-225 based antibody radiation conjugate targeting CD33, a validated target that is expressed in virtually all patients with AML. Actimab-A due to its radiation modality is agnostic to cytogenetics.
Lead Product(s): Lintuzumab-Ac225,Cladribine,Cytarabine
Therapeutic Area: Oncology Product Name: Actimab-A
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Actinium pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2022
Details:
ADXS-504 is a novel Lm-based immunotherapy, bioengineered to elicit T cell responses against 24 tumor antigens, including 14 peptide antigens derived from hotspot mutations in patients with prostate cancer.
Lead Product(s): ADXS-504
Therapeutic Area: Oncology Product Name: ADXS-504
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Ayala Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
RenovoRx’s lead product candidate, RenovoGem, is a combination of gemcitabine and the patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: Gemzar
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: RenovoRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
BridgeBio has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet need as quickly and safely as possible.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2021
Details:
Under the agreement, Silo has been granted an option to license psychedelics as a therapeutic currently under development, for Alzheimer’s disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Silo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2021
Details:
The research collaboration is focused on studying immune responses to COVID-19 as well as studying in vitro T cell and antibody responses to SARS-CoV-2, by developing TNX-1800, a modified horsepox virus that is designed to express a protein from the virus that causes COVID-19.
Lead Product(s): TNX-1800
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-1800
Highest Development Status: IND EnablingProduct Type: Vaccine
Recipient: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 23, 2021
Details:
The study also reports trends towards improved clinical status among patients who received convalescent plasma less than seven days after symptom onset and those who received convalescent plasma with higher-titers of neutralizing antibodies and concomitant corticosteroids.
Lead Product(s): Convalescent plasma
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
